Consistency of response across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Reich, Kristian ^{[2
]}

Papp, Kim A. ^{[3
]}

Griffiths, Christopher E. M. ^{[4
]}

Armstrong, April W. ^{[5
]}

Foley, Peter ^{[6
,7
]}

Shen, Yaung-Kaung ^{[8
]}

Kimball, Alexa B. ^{[9
]}

Gordon, Kenneth B. ^{[10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Dermatologikum Hamburg, Hamburg, Germany

[3] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada

[4] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England

[5] Univ Southern Calif, Los Angeles, CA USA

[6] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[7] Skin & Canc Fdn Inc, Carlton, Vic, Australia

[8] Janssen Res & Dev LLC, Raritan, NJ USA

[9] Harvard Med Sch, Dept Dermatol, Boston, MA USA

[10] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

4895

引用

页码：AB83 / AB83

页数：1

共 50 条

[41] Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Reich, Kristian
Dutz, Jan
Foley, Peter
Thaci, Diamant
Vender, Ron
Song, Michael
Miller, Megan
Yu, Yin
Li, Shu
Shen, Yaung-Kaung
Armstrong, April W.
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[42] Guselkumab in patients with scalp psoriasis: A post hoc analysis of the VOYAGE 2 trial
Savage, Laura
Sonkoly, Eniko
Maul, Julia-Tatjana
Fabbrocini, Gabriella
Gorecki, Patricia
Crombag, Edmee
Buyze, Jozefien
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB51 - AB51
[43] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatment: Voyage 1&2 trials
Puig, L.
Tsai, T.
Bhutani, T.
Uy, J.
Ramachandran, P.
Song, M.
You, Y.
Gooderham, M.
Lebwohl, M.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 81 - 81
[44] Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
Papp, K. A.
Blauvelt, A.
Kimball, A. B.
Han, C.
Randazzo, B.
Wasfi, Y.
Shen, Y. -K.
Li, S.
Griffiths, C. E. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1515 - 1522
[45] Malignancy rates and comparisons to the general US population through 3 years of follow-up in guselkumab-treated patients with moderate to severe psoriasis from the VOYAGE 1 and 2 trials
Papp, Kim A.
Reich, Kristian
Gordon, Ken B.
Kimball, Alexa B.
Ramachandran, Paraneedharan
Blauvelt, Andrew
Lebwohl, Mark
Song, Michael
Randazzo, Bruce
Shen, Yaung-Kaung
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
[46] Comparisons of symptom-free and sign-free status among patients with moderate to severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1
Griffiths, Christopher E. M.
Philipp, Sandra
Bagel, Jerry
Han, Chenglong
Song, Michael
Huang, Yu-Huei
Adam, David N.
Bhutani, Tina
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB34 - AB34
[47] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
Puig, L.
Tsai, T. -F.
Bhutani, T.
Uy, J.
Ramachandran, P.
Song, M.
You, Y.
Gooderham, M.
Lebwohl, M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
[48] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Blauvelt, Andrew
Tsai, Tsen-Fang
Langley, Richard G.
Miller, Megan
Shen, Yaung-Kaung
You, Yin
Yang, Ya-Wen
Papp, Kim A.
Puig, Luis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
[49] COMPARING EFFICACY OF GUSELKUMAB VERSUS USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS : AN ADJUSTED COMPARISON BASED ON VOYAGE 1&2 AND NAVIGATE TRIALS
Diels, J.
Thilakarathne, P.
Schubert, A.
McElligott, S.
VALUE IN HEALTH, 2017, 20 (09) : A544 - A545
[50] Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population
Papp, Kim A.
Reich, Kristian
Gordon, Kenneth B.
Lebwohl, Mark
Song, Michael
Miller, Megan
Ramachandran, Paraneedharan
Shen, Yaung-Kaung
Lin, Connie B.
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB157 - AB157

← 1 2 3 4 5 →